Figure 2.

Infected cell protein 0–null herpes simplex viruses (HSVs) possess equivalent in vivo antitumor properties in the HER-2/neu murine breast cancer model. Subcutaneous HER-2/neu breast tumor-bearing wt FVB mice were intratumorally treated with three doses of 2 × 10⁷ pfu of either n212 or KM100 or an equivalent amount of phosphate-buffered saline (PBS) on days 0, 1 and 3. (a) Kaplan–Meier survival analysis of ICP0-null HSV treatments. Statistical significance was determined by the log-rank test, where P < 0.05. (b) Intergroup comparisons of the fold changes in HER-2/neu tumor volume within each ICP0-null HSV or PBS control group. Statistical significance was determined by the Koziol distribution free test when P < 0.001.³³ (c) Intragroup comparisons of the fold changes in HER-2/neu tumor volume measurements between the PBS control (upper panel), n212 (lower left), and KM100 (lower right) treatment groups. Error bars indicate SE of experimental means within treatment groups from a and b. Arrows indicate time of virus injection. Data were generated from 10 mice per treatment group, combined from two independent experiments.